Sestina Bio, a synthetic biology company, used proprietary data for at-scale strain-performance prediction and developed a ready-to-scale Bakuchiol-producing microbial strain.
Sestina Bio, an East Bay synthetic biology company, has been acquired by a former partner. The deal consolidates three firms—including Sestina Bio—into a single entity, combining distinct biomanufacturing technologies. The move aims to integrate their respective expertise in synthetic biology applications.
Inscripta acquires Infinome Biosciences and Sestina Bio to expand its capabilities in **biomanufacturing**. The move follows **dozens of layoffs** and **two site closures** in December, signaling a strategic shift in the company’s operations.
Inscripta acquires Infinome Biosciences and Sestina Bio to expand its genome engineering technology for industrial and consumer bio-manufactured products. The move strengthens Inscripta’s focus on sustainable synthetic biology solutions. Both acquired companies specialize in developing scalable biological systems for diverse applications.
Sestina Bio develops a microbial strain using Inscripta’s Onyx platform to produce Bakuchiol, a natural alternative to retinol. The strain is now ready for scale-up within under 12 months. This achievement accelerates production of a high-demand skincare ingredient through synthetic biology.
Sestina Bio has launched a platform for automated synthetic biology, focusing on single-cell engineering. The company secures seed funding from Foresite Capital, General Inception, and OMX Ventures to advance its digital cellular engineering and phenotyping technologies. It is the first startup to emerge from Foresite Labs incubator.